Vaccine

Typhoid fever vaccines
pp. 1433-1434(2)
Authors: Engels E.A.; Bennish M.L.; Falagas M.E.; Lau J.

Potential of DNA vaccines delivered by influenza virosomes
pp. 1435-1435(1)
Authors: Cusi M.G.; Gluck R.

Vaccines in historic evolution and perspective: a narrative of vaccine discoveries
pp. 1436-1447(12)
Author: Hilleman M.R.

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais
pp. 1448-1455(8)
Authors: Nitayaphan S.; Khamboonruang C.; Sirisophana N.; Morgan P.; Chiu J.; Duliege A.-M.; Chuenchitra C.; Supapongse T.; Rungruengthanakit K.; deSouza M.; Mascola J.R.; Boggio K.; Ratto-Kim S.; Markowitz L.E.; Birx D.; Suriyanon V.; McNeil J.G.; Brown A.E.; Michael R.A.

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age
pp. 1456-1466(11)
Authors: de Kleijn E.D.; de Groot R.; Labadie J.; Lafeber A.B.; van den Dobbelsteen G.; van Alphen L.; van Dijken H.; Kuipers B.; van Omme G.-W.G.-W.; Wala M.; Juttmann R.; Rumke H.C.

Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children
pp. 1467-1472(6)
Authors: Duval B.; Boulianne N.; De Serres G.; Laflamme N.; De Wals P.; Masse R.; Trudeau G.; Delage G.; Desjardins L.

Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity
pp. 1473-1484(12)
Authors: Dilts D.A.; Riesenfeld-Orn I.; Fulginiti J.P.; Ekwall E.; Granert C.; Nonenmacher J.; Brey R.N.; Cryz S.J.; Karlsson K.; Bergman K.; Thompson T.; Hu B.; Bruckner A.H.; Lindberg A.A.

The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly
pp. 1485-1494(10)
Author: Gessner B.D.

Vaccine properties of antigens entrapped in microparticles produced by spray-drying technique and using various polyester polymers
pp. 1495-1505(11)
Authors: Baras B.; Benoit M.-A.; Poulain-Godefroy O.; Schacht A.-M.; Capron A.; Gillard J.; Riveau G.

Immunization with a DNA expression vector encoding the varicella zoster virus glycoprotein E (gE) gene via intramuscular and subcutaneous routes
pp. 1506-1514(9)
Authors: Hasan U.A.; Harper D.R.; Argent S.; Layton G.; Wren B.W.; Morrow W.J.W.

Cattle immune responses to tetanus toxoid elicited by recombinant S. typhimurium vaccines or tetanus toxoid in alum or Freund's adjuvant
pp. 1515-1521(7)
Authors: Villarreal-Ramos B.; Manser J.M.; Collins R.A.; Dougan G.; Howard C.J.

Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver
pp. 1522-1530(9)
Authors: Rogers J.V.; Hull B.E.; Fink P.S.; Chiou H.C.; Bigley N.J.

Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines
pp. 1531-1538(8)
Authors: Heijtink R.A.; van Bergen P.; Paulij W.P.; de Man R.A.; Osterhaus A.D.M.E.

Vaccine nomenclature: the three-letter code
pp. 1539-1542(4)
Author: Maurer W.

Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein
pp. 1543-1554(12)
Authors: Djavani M.; Yin C.; Xia L.; Lukashevich I.S.; Pauza C.D.; Salvato M.S.

Gelatin-containing diphtheria-tetanus-pertussis (DTP) vaccine causes sensitization to gelatin in the recipients
pp. 1555-1561(7)
Authors: Kumagai T.; Ozaki T.; Kamada M.; Igarashi C.; Yuri K.; Furukawa H.; Wagatuma K.; Chiba S.; Sato M.; Kojima H.; Saito A.; Okui T.; Yano S.